Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GE

- PMLiVE

Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy

Around 160,000 people worldwide are estimated to be diagnosed with DLBCL each year

- PMLiVE

Roche launches two antibodies to identify mutation status in brain cancer patients

Knowing a patient’s key mutations can help clinicians provide personalised care

- PMLiVE

Paris Court of Appeal overturns Novartis and Roche’s €444m anti-competitiveness fine

It was questioned whether the companies had used their market power to boost sales of their eye disease drug

- PMLiVE

Roche reports positive results for crovalimab as rare blood disease treatment

The drug was shown to be as effective as current treatment, with less frequent dosing

- PMLiVE

Roche’s Polivy recommended by NICE for lymphoma therapy

Around 5,500 people in England are diagnosed with the aggressive blood cancer each year

Diversifying Healthcare AI with Federated Learning

Dr. Ittai Dayan, Co-founder & CEO of Rhino Health, shares how his company is transforming the way healthcare AI solutions are created, adopted and measured. He will also explore how...

Impetus Digital

- PMLiVE

Genentech reports positive phase 3 data for its Tecentriq combination in liver cancer

Tecentriq in combination with Avastin significantly improved recurrence-free survival

Repurposing Off-Patent Drugs Through Crowd Funding

Savva Kerdemelidis, Founder & CEO of Crowd Funded Cures, explores the concepts of interventional pharmacoeconomics and pay-for-success contracts to fund new uses for off-patent drugs and other unmonopolizable therapies. 

Impetus Digital

- PMLiVE

Roche’s influenza medicine approved by EC for children

Xofluza is now the first single-dose, oral influenza medicine approved in Europe for children

- PMLiVE

Roche’s COVID-19 antibody receives FDA approval for hospitalised adults

The decision makes Actemra the first FDA-approved monoclonal antibody to treat COVID-19

- PMLiVE

Novartis partners with Cancer Research UK for rare cancer trial

The trial enrolled both paediatric and adult patients with any rare form of cancer

- PMLiVE

Roche shares phase 3 Polivy data for previously untreated diffuse large B-cell lymphoma

Results continue to show significant reduction in risk of death for DLBCL patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links